论文部分内容阅读
1964年作者和Krahe首次报道人体恶性肿瘤组织培养,并对各种细胞抑制剂作敏感试验。在人体,化疗仅对一定比例的病例有效,无效病例化疗对机体有害。因此,作者对每例人体肿瘤只做短期培养,取出瘤细胞在体外对一系列化疗药物作敏感试验,需要时做体内试验,根据敏感试验结果制订治疗方案。作者16年来前瞻性研究191例原发性卵巢癌,所有治疗皆在同一治疗中心进行,80%病例入院时已为UICCT_4期或FIGOⅢ、Ⅳ期,其中乳头状浆液性癌占56.5%。将原发瘤和转移瘤组织用Dulbecco和Vogt改良的胰蛋白酶消化法培养,94%可获成功。敏感试验亦可在术前进行,在足量的腹水中无
In 1964, the authors and Krahe first reported human malignant tumor tissue culture and made sensitive tests on various cytostatics. In the human body, chemotherapy is only effective for a certain percentage of cases, ineffective case chemotherapy is harmful to the body. Therefore, the author of each case of human tumors only short-term culture, remove the tumor cells in vitro for a series of chemotherapeutic drugs for sensitive test, if necessary, do in vivo test, the sensitivity of the test results to develop treatment options. The author prospectively studied 191 cases of primary ovarian cancer for 16 years. All the treatments were performed in the same treatment center. Eighty percent of cases had been admitted to UICCT_4 or FIGOⅢ and Ⅳ stages, of which 56.5% were papillary serous carcinomas. Primary and metastatic tumor tissues were cultured with modified trypsin digestion by Dulbecco and Vogt and 94% were successful. Sensitization tests can also be performed preoperatively, in a sufficient amount of ascites